Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McTernan, P. G.
Right arrow Articles by Kumar, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McTernan, P. G.
Right arrow Articles by Kumar, S.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 51:1493-1498, 2002
© 2002 by the American Diabetes Association, Inc.

Insulin and Rosiglitazone Regulation of Lipolysis and Lipogenesis in Human Adipose Tissue In Vitro

Philip G. McTernan1, Alison L. Harte1, Leah A. Anderson1, Allan Green2, Stephen A. Smith3, Julie C. Holder3, Anthony H. Barnett1, Margaret C. Eggo1, and Sudhesh Kumar1

1 Division of Medical Sciences, Department of Medicine, University of Birmingham and Heartlands Hospital, Edgbaston, Birmingham, U.K.
2 Bassett Research Institute, Cooperstown, NY
3 Glaxo-SmithKline, Harlow, U.K.

Lipolysis is an important process determining fuel metabolism, and insulin regulates this process in adipose tissue. The aim of this study was to investigate the long-term effects of insulin, an insulin enhancer (rosiglitazone [RSG]), and insulin in combination with RSG on the regulation of lipolysis and lipogenesis in human abdominal subcutaneous fat. Lipolysis and lipogenesis were assessed by protein expression studies of hormone-sensitive lipase (HSL) (84 kDa) and lipoprotein lipase (LPL) (56 kDa), respectively. In addition, lipolytic rate was assessed by glycerol release assay and tumor necrosis factor (TNF)-{alpha} release measured by enzyme-linked immunosorbent assay (n = 12). In subcutaneous adipocytes, increasing insulin doses stimulated LPL expression, with maximal stimulation at 100 nmol/l insulin (control, 1.0 ± 0.0 [mean ± SE, protein expression relative to control]; 1 nmol/l insulin, 0.87 ± 0.13; 100 nmol/l insulin, 1.68 ± 0.19; P < 0.001). In contrast, insulin at the 100 nmol/l dose reduced the expression of HSL (100 nmol/l insulin, 0.49 ± 0.05; P < 0.05), while no significant reduction was observed at other doses. Higher doses of insulin stimulated both HSL (1,000 nmol/l insulin, 1.4 ± 0.07; P < 0.01) and LPL (control 1.00 ± 0.0; 1,000 nmol/l insulin, 2.66 ± 0.27; P < 0.01) protein expression. Cotreatment with RSG induced an increased dose response to insulin for LPL and HSL (P < 0.05); RSG alone also increased LPL and HSL expression (P < 0.05). Insulin stimulated TNF-{alpha} secretion in a dose-dependent manner (P < 0.01); the addition of RSG (10-8 mol/l) reduced TNF-{alpha} secretion (P < 0.05). In summary, chronic treatment of human adipocytes with insulin stimulates lipolysis and LPL protein expression. The addition of RSG reduced the lipolytic rate and TNF-{alpha} secretion. The increase in lipolysis is not explained by changes in HSL expression. These data, therefore, may explain in part why hyperinsulinemia coexists with increased circulating nonesterified free fatty acids and increased adiposity in obese and/or type 2 diabetic patients.



Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J EndocrinolHome page
G. Liu, M. Grifman, J. Macdonald, P. Moller, F. Wong-Staal, and Q.-X. Li
Isoginkgetin enhances adiponectin secretion from differentiated adiposarcoma cells via a novel pathway involving AMP-activated protein kinase
J. Endocrinol., September 1, 2007; 194(3): 569 - 578.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
A. Purushotham, A. A. Wendel, L.-F. Liu, and M. A. Belury
Maintenance of adiponectin attenuates insulin resistance induced by dietary conjugated linoleic acid in mice
J. Lipid Res., February 1, 2007; 48(2): 444 - 452.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
G. Ranganathan, R. Unal, I. Pokrovskaya, A. Yao-Borengasser, B. Phanavanh, B. Lecka-Czernik, N. Rasouli, and P. A. Kern
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment
J. Lipid Res., November 1, 2006; 47(11): 2444 - 2450.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
S. Guldiken, B. Turgut, M. Demir, E. Arikan, M. Kara, O. Vural, A. Tugrul, and J. Fareed
The Effects of Rosiglitazone Treatment on the Fibrinolytic System in Patients with Type 2 Diabetes Mellitus
Clinical and Applied Thrombosis/Hemostasis, January 1, 2006; 12(1): 55 - 60.
[Abstract] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. Sutinen, K. Kannisto, E. Korsheninnikova, R. M. Fisher, E. Ehrenborg, T. Nyman, A. Virkamaki, T. Funahashi, Y. Matsuzawa, H. Vidal, et al.
Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E941 - E949.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. Faraj, A. D. Sniderman, and K. Cianflone
ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes
J. Lipid Res., April 1, 2004; 45(4): 657 - 666.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. Green, J. M. Rumberger, C. A. Stuart, and M. S. Ruhoff
Stimulation of Lipolysis by Tumor Necrosis Factor-{alpha} in 3T3-L1 Adipocytes Is Glucose Dependent: Implications for Long-Term Regulation of Lipolysis
Diabetes, January 1, 2004; 53(1): 74 - 81.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. G. McTernan, F. M. Fisher, G. Valsamakis, R. Chetty, A. Harte, C. L. McTernan, P. M. S. Clark, S. A. Smith, A. H. Barnett, and S. Kumar
Resistin and Type 2 Diabetes: Regulation of Resistin Expression by Insulin and Rosiglitazone and the Effects of Recombinant Resistin on Lipid and Glucose Metabolism in Human Differentiated Adipocytes
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6098 - 6106.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
T. Matsuki, R. Horai, K. Sudo, and Y. Iwakura
IL-1 Plays an Important Role in Lipid Metabolism by Regulating Insulin Levels under Physiological Conditions
J. Exp. Med., September 15, 2003; 198(6): 877 - 888.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
K. A. Virtanen, K. Hallsten, R. Parkkola, T. Janatuinen, F. Lonnqvist, T. Viljanen, T. Ronnemaa, J. Knuuti, R. Huupponen, P. Lonnroth, et al.
Differential Effects of Rosiglitazone and Metformin on Adipose Tissue Distribution and Glucose Uptake in Type 2 Diabetic Subjects
Diabetes, February 1, 2003; 52(2): 283 - 290.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
N. G. Patel, J. C. Holder, S. A. Smith, S. Kumar, and M. C. Eggo
Differential Regulation of Lipogenesis and Leptin Production by Independent Signaling Pathways and Rosiglitazone During Human Adipocyte Differentiation
Diabetes, January 1, 2003; 52(1): 43 - 50.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. Motoshima, X. Wu, M. K. Sinha, V. E. Hardy, E. L. Rosato, D. J. Barbot, F. E. Rosato, and B. J. Goldstein
Differential Regulation of Adiponectin Secretion from Cultured Human Omental and Subcutaneous Adipocytes: Effects of Insulin and Rosiglitazone
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5662 - 5667.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.